

Pharmahungary Group Press release

Péter Ferdinandy, MD, PhD, MBA, the Founder & CEO of Pharmahungary Group, has been recognized as a 'Highly Cited Researcher' for the sixth time in 2023.

Budapest, Hungary, December 11, 2023. Péter Ferdinandy, MD, PhD, MBA, the Founder & CEO of [Pharmahungary Group](http://www.pharmahungary.com) has been noticed as a ['Highly Cited Researcher'](#) for the 6th time in 2023. The 'Highly Cited Researcher' list is compiled by [Clarivate](#) includes less than 7,200 researchers worldwide in all disciplines who authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade.

The 'Highly Cited Researchers' list for 2023 has been unveiled by Clarivate. This year less than 7,200 researchers have earned the recognition of 'Highly Cited Researchers' across all research fields. 'Highly Cited Researchers' authored multiple Highly Cited Papers™, ranking within the top 1% by citations for their respective field and year within the Web of Science™ database. However, citation activity is not the sole selection indicator. A preliminary list based on citation activity is then refined using qualitative analysis and expert judgement.

Prof. Ferdinandy was acknowledged for the 6th time in 2023 as a 'Highly Cited Researcher' after 2014, 2017, 2020, 2021, and 2022. Considered as a key opinion leader in the pharmacology of cardioprotection, Prof. Ferdinandy also holds academic positions such as the Head of the [Department of Pharmacology and Pharmacotherapy](#) and the Vice-Rector for Science and Innovations of [Semmelweis University](#), Budapest, Hungary. Moreover, he is the Editor-in-Chief of [British Journal of Pharmacology](#) since January 1st, 2023, the President of the [Hungarian Society for Experimental and Clinical Pharmacology](#) and Executive Committee member of the [European Federation of Pharmacological Societies](#).

About Pharmahungary Group

Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003. More information: www.pharmahungary.com.

Contact Pharmahungary Group

Andras Nogradi, Business Development Director

Graphisoft Park, Zahony str. 7., Budapest, H-1031, Hungary, European Union

e-mail: businessdevelopment@pharmahungary.com